Petition to Establish the Advanced Approval Pathway for Longevity Medicines (AAPLM)
CONGRESS, THE LONGEVITY SCIENCE CAUCUS (LSC), AND FOOD AND DRUG ADMINISTRATION (FDA)
The Advanced Approval Pathway for Longevity Medicines (AAPLM) aims to incentivize the development of longevity therapies by aligning economic benefits with public health improvements. This pathway includes three key provisions: (1) a faster approval process for longevity medicine, (2) transferable Priority Review Vouchers (PRVs), and (3) patent extensions granted on a per-indication basis. These incentives allow companies to bring therapies to market more quickly, improve financial stability through voucher sales, and increase asset value for investors through patent extensions, supporting broader, longer-term clinical development and trials for age-related diseases.
By signing this petition, you support the creation of the Advanced Approval Pathway for Longevity Medicines (AAPLM) that will help companies accelerate their developments and approvals of therapies targeting aging and age-related multi-morbidities, expanding access to innovative treatments. Together, we can advance public health, enhance quality of life, and drive economic growth by fostering groundbreaking solutions to the challenges of aging.
Sponsored by
To:
CONGRESS, THE LONGEVITY SCIENCE CAUCUS (LSC), AND FOOD AND DRUG ADMINISTRATION (FDA)
From:
[Your Name]
We, the undersigned, strongly support the establishment of the Advanced Approval Pathway for Longevity Medicines (AAPLM) as proposed by the Alliance for Longevity Initiatives (A4LI).
The AAPLM aims to incentivize the development of longevity therapies by aligning economic benefits with public health improvements. Its three core provisions—a special approval track, a transferable priority review voucher system, and patent term extensions granted on a per-indication basis, will encourage investment in the field, increase financial incentives, and facilitate clinical development of innovative therapies for age-related diseases and multi-morbidities.
By promoting the development and approval of groundbreaking longevity medicines, the AAPLM has the potential to improve individual health and autonomy, address diverse unmet medical needs, and expand access to innovative treatments. Additionally, this pathway would reduce healthcare costs, increase workforce productivity, and generate substantial social and economic gains and stability. These benefits make the AAPLM a critical policy reform for the future of healthcare and society as a whole.
Therefore, we call upon Congress, the Longevity Science Caucus, and the Food and Drug Administration to establish the AAPLM in order to accelerate the development and approval of longevity medicines. Thank you for your attention to this critical issue.